OPKO Health, Inc. (OPK)

NMS – Цена в реальном времени. Валюта: USD

1.10

-0.02 (-1.79%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.10

0.00 (0.00%)

До открытия: May 13, 2026, 4:19 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

OPKO Health, Inc. (OPK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

OPKO Health, Inc. (OPK)

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y

OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript

OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates

Видео

No Data

Пресс-релизы

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

Search stocks

OPKO Health, Inc. (OPK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

OPKO Health, Inc. (OPK)

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y

OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript

OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates

Видео

No Data

Пресс-релизы

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results